Skip to content
Donate
kcnq2 logo
  • KCNQ2 EPILEPSY
    • What is KCNQ2 Epilepsy
    • Newly Diagnosed
    • Family Supports
    • Contact Registry
    • FAQ
    • Our Stories
    • News and Media
    • In Loving Memory
  • RESEARCH
    • Participate in Research
    • Clinical Trials
    • Research Review
    • Grant Program
  • GET INVOLVED
    • Fundraise
    • Volunteer
    • Awareness
    • Share Your Story
    • Ways to Give
  • EVENTS
    • Conference
      • 2023 Summit
      • 2022 Summit
      • 2021 Summit
      • 2018 Summit
      • 2017 Summit
      • 2016 Summit
      • 2015 Summit
      • 2014 Summit
    • Awareness Week
    • Webinars
    • Upcoming Events
  • OUR ROLE
    • Our Team
    • Scientific Advisory Board
    • Global Reach
    • Newsletter
    • Blog
    • Finances
    • Contact Us
  • DONATE

Press Releases

News and Media / Press Releases

Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference

May 24, 2019
Read More

Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update

March 6, 2019
Read More

Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

February 26, 2019
Read More

Xenon Pharmaceuticals Outlines 2019 Key Milestones

January 6, 2019
Read More

Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

November 6, 2018
Read More

Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy

September 6, 2018
Read More

NINDS Launches New Epilepsy Center Without Walls

August 1, 2018
Read More

Pairnomix And KCNQ2 Cure Alliance Report Findings From Comprehensive Drug Screening In A Cellular Model Of KCNQ2 Epileptic Encephalopathy

December 4, 2017
Read More

Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial

October 17, 2017
Read More

Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy

April 26, 2017
Read More
  • 1
  • 2
  • Next »

Contact Us

(720) 772-1433

3700 Quebec Street Unit 100-118 Denver, CO 80207

info@kcnq2cure.org

About Us

The KCNQ2 Cure Alliance is a 501(c)3 non-profit organization (EIN #47-1810644). All donations are tax-deductible to the extent the law allows.

Privacy Policy

Follow Us

Email Sign Up

Subscribe

* indicates required



Relationship *

  •  
  •  
  •  
  •  
 
 

©2023 KCNQ2 Cure Alliance. All Rights Reserved.